A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

• Status: Completed
• Trial end date: 2018-12-26
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Dasatinib; Nivolumab

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Confirmed diagnosis of Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase :

• With historically documented Ph+ cells

• ≥2 prior Tyrosine Kinase Inhibitors (TKI) therapies for CML

• Currently progressing, resistance to or with a suboptimal response to their most recent therapy

• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score 0 - 1

Exclusion Criteria:

• Blast phase CML

• Known Abl-kinase mutation resistant to Dasatinib (e.g. T315I or T315A)